Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Derek J Jonker, Chris Karapetis, Christopher T Harbison, Chris J O'Callaghan, Dongsheng Tu, R John Simes, Daniel P Malone, Christiane Langer, Niall Tebbutt, Timothy J Price, Jeremy Shapiro, Lillian L Siu, Ralph P W Wong, Georg A Bjarnason, Malcolm J Moore, John Raymond Zalcberg, Shirin Khambata-Ford

Research output: Contribution to journalArticleResearchpeer-review

66 Citations (Scopus)


Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit.Methods:Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction.Results:Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ( co-biomarker )-positive group (n=139, 36 ), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P
Original languageEnglish
Pages (from-to)648 - 655
Number of pages8
JournalBritish Journal of Cancer
Issue number3
Publication statusPublished - 2014

Cite this